Micafungin Sodium is Used for treating candidiasis infections in various settings, including esophageal candidiasis, candidemia, and candida peritonitis. It was first introduced by Astellas Pharma Us Inc in its drug Mycamine on Mar 16, 2005. Other drugs containing Micafungin Sodium are Micafungin, Micafungin In Sodium Chloride 0.9%. 13 different companies have introduced drugs containing Micafungin Sodium.

Micafungin Sodium Patents

Given below is the list of patents protecting Micafungin Sodium, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Mycamine	US6774104 (Pediatric)	Stabilized pharmaceutical composition in lyophilized form	Jul 08, 2021 (Expired)	Astellas
Mycamine	US6774104	Stabilized pharmaceutical composition in lyophilized form	Jan 08, 2021 (Expired)	Astellas
Mycamine	US6107458	Cyclic hexapeptides having antibiotic activity	Mar 16, 2019 (Expired)	Astellas
Mycamine	US6265536	Cyclic hexapeptides having antibiotic activity	Sep 29, 2015 (Expired)	Astellas

Add above patents to watchlist

Micafungin Sodium's Family Patents

Full family tree

Micafungin Sodium Generic API Manufacturers

Several generic applications have been filed for Micafungin Sodium. The first generic version for Micafungin Sodium was by Fresenius Kabi Usa Llc and was approved on May 17, 2019. And the latest generic version is by Qilu Pharmaceutical Hainan Co Ltd and was approved on Apr 3, 2025.

Given below is the list of companies who have filed for Micafungin Sodium generic, along with the locations of their manufacturing plants worldwide.